Collateral for a security interest recorded Mar 31, 2025 (Ligand Pharmaceuticals Incorporated).
Term ends Sep 1, 2036 · High confidence
20-year base term ends Sep 1, 2036
Held by Agenus Inc.
Filed Apr 24, 2020 as application 16/858,193 · Granted May 31, 2022
Base term plus 82 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
2016
2036
Clock starts
Sep 1, 2016
Sep 1, 2016
Term ends
Sep 1, 2036
Sep 1, 2036
Granted
May 31, 2022
May 31, 2022
base term
fee events
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
82
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 10,323,091, US 10,450,373.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
5
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 82 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 1 of 3 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Sep 1, 2016, when application 15/254,315, the earliest non-provisional in its chain, was filed (this one was filed Apr 24, 2020) | Sep 1, 2036 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +82 days, USPTO patent term adjustment record | Nov 22, 2036 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,323,091, US 10,450,373) | capped to Sep 1, 2036 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Sep 1, 2036 | High confidence |
This family
| US 10,323,091 | In force Oct 2037 | Oct 2037 |
| US 10,450,373 | In force Sep 2036 | Sep 2036 |
| Application 16/570,260 | Abandoned not computed | not computed |
| US 11,345,755 | this patent Sep 2036 | Sep 2036 |
| Application 17/662,518 | Abandoned not computed | not computed |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Mar 30, 2021 Reel 55767, frame 706 | Van Dijk, Marc; Mundt, Cornelia Anne | 4-Antibody AG | Assignment of Assignor's Interest |
| Mar 30, 2021 Reel 55768, frame 205 | Savitsky, David Adam; Wilson, Nicholas Stuart | Agenus Inc. | Assignment of Assignor's Interest |
| Mar 30, 2021 Reel 55768, frame 251 | 4-Antibody AG | Agenus Inc. | Assignment of Assignor's Interest |
| Mar 30, 2021 Reel 55768, frame 342 | Wolchok, Jedd David; Merghoub, Taha; Zappasodi, Roberta; Holmgaard, Rikke Baek; Schaer, David | Memorial Sloan Kettering Cancer Center | Assignment of Assignor's Interest |
| Mar 30, 2021 Reel 55768, frame 422 | Ritter, Gerd | Ludwig Institute for Cancer Research Ltd. | Assignment of Assignor's Interest |
| Mar 31, 2025 Reel 70680, frame 634 | Agenus, Inc. | Ligand Pharmaceuticals Incorporated | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Sep 2036
Term ends Sep 1, 2036. Maintenance fees still fall due before then
Note
The 82 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 10,323,091, US 10,450,373.
Citations
1
later US patent cites this one
That is below the median of utility patents granted in 2022 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.